Healthcare
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Phrase
Broad biopharma
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 1in the latest 2
Mood and coverage · last 7 days
Market chart- Broad biopharma · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sun, Oct 11 | — | 0 |
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
Latest on Broad biopharma
Newest firstHealthcare
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
The biopharmaceutical sector has struggled with a prolonged downturn in recent years but has been on an upswing of late.
